Compare Alexandria Real Estate Equities Inc (ARE) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Cytokinetics Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.32B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Alexandria Real Estate Equities Inc pays a 5.96% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| ARE | CYTK | |
|---|---|---|
Market Cap | $8.32B | $10.78B |
Sector | Real Estate | Technology |
52-Week High | $87.45 | $87.26 |
52-Week Low | $40.41 | $34.31 |
Enterprise Value | $21.02B | $10.88B |
Dividend Yield | 5.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $49.74, up 2.6% on the day, yet technical indicators signal a bearish trend with support near $47. The stock shows mixed fundamentals: a high P/E of 102.99 and negative net income margin of -37.12% contrast with strong FFO beats and a dividend payout. Recent Q2 2026 earnings missed on EPS but beat on FFO, with leasing momentum improving. Analyst consensus is a 'Hold' with a $53.71 price target, indicating modest upside potential amid operational challenges.
Outlook remains cautious due to persistent net losses and high debt, though leasing recovery and institutional interest offer hope. Risks include occupancy pressures and macroeconomic headwinds, but the current discount to book value (P/B 0.55) may attract value investors if operational trends stabilize.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
